HomeBUSINESS
BUSINESS

1st Patient Enrolled in PII/III for Healios’ Sakigake-Designated Stem Cell Therapy
(Nov.17.2017)

Healios, a Tokyo based cell therapy developer, has enrolled the first patient in a Japanese PII/III trial for the off-the-shelf cell therapy product HLCM051, also known as MultiStem, for the treatment of ischemic stroke ...
(LOG IN FOR FULL STORY)